RxDoctor Payments Data

Kavita Krishnasamy, MD

Clinical Cardiac Electrophysiology · Fayetteville, GANPI 1407099575

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (46.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Biotronik Inc. accounts for 68.5% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $26,418, more than ten times the $216 reported in 2019.

$37,054in general payments, 2019–2025

Across 99 payments — averaging $374.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$25K
  • Biosense Webster, Inc.$8K
  • Medtronic$972
  • Abbott$590
  • Boston Scientific$468
  • Acutus Medical, Inc.$209
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$5,62515%
  • Grants$17,32547%
  • Travel & lodging$9,42425%
  • Food & beverage$4,61112%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,054 in reported general payments places this provider in the 65th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$306,384
Medicare patients
678
Services billed
4,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban634$681,499
XareltoRivaroxaban131$151,429
Dofetilide108$14,446
Amiodarone Hcl292$8,102
Flecainide Acetate163$6,613
Metoprolol Succinate277$5,266
Propafenone Hcl ErPropafenone Hcl16$4,099
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$2,266
Midodrine Hcl18$1,359
Metoprolol Tartrate184$1,125
SotalolSotalol Hcl35$654
Digoxin32$596
PaceroneAmiodarone Hcl14$441
Pantoprazole Sodium32$271
Carvedilol36$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$681,499634 claims
Johnson & JohnsonXarelto$62$151,429131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →